ESI gets rights to diabetes technology
Thursday, 19 December, 2002
Singapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Under the terms of the agreement, ESI will be responsible for continuing the development and testing of Curis' diabetes stem cell technologies.
According to Robert Klupacs, CEO of ESI, the acquisition will enhance ESI's diabetes cell therapy program and complements other technology the company has licensed in for the program.
"Accessing both Curis' world-class technologies and research capabilities will significantly accelerate our ability to bring cell-based therapies for diabetes to the clinic," Klupacs said in a statement.
ESI is developing therapeutic technologies for the treatment of diabetes and Parkinson's disease using embryonic and adult stem cells.
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
Prenatal stress leaves a molecular mark on newborns
An international study has uncovered how stress experienced during pregnancy can affect newborns...
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
